Despite a beneficial response to treatment with intravenous immunoglobulins (IVIg), weakness is slowly progressive. Histopathological studies in MMN revealed features of demyelination and axon loss.

Axon Enterprise (AXON) reached $610.32, with a -0.5% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. On the other hand, the Dow ...